Alterity Therapeutics Ltd ADR (ATHE) Stock Price, Quote & News

Company Profile

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202...

Industry: Biotechnology

Sector: Healthcare

Phone: 61 3 9349 4906

Fax: 61 3 9349 4906

Website: alteritytherapeutics.com

Address:

350 Collins Street, Suite 4 Level 14, Melbourne, Australia

stckmuncher Dec. 2 at 12:35 AM

$ATHE Can anyone explain what in in the furry fuck is going on?

0 · Reply

Dingo2 Dec. 1 at 4:34 PM

$ATHE LOL - thinly traded and someone is parking 47k on ask? Sure…

1 · Reply

stckmuncher Dec. 1 at 3:48 AM

$ATHE HUGE YEAR COMING!!!!!!!!!!!!!!!!

0 · Reply

GA09 Nov. 30 at 11:40 PM

$ATHE https://www.youtube.com/watch?v=yZo-2w7r3cg Presentation at the Bell Potter Conference 2025

2 · Reply

GA09 Nov. 30 at 11:39 PM

$ATHE The CEO's presentation at the Bell Potter Healthcare Conference 2025 is now available in the Events Section on their website.

0 · Reply

stckmuncher Nov. 28 at 3:16 PM

$ATHE

0 · Reply

stckmuncher Nov. 28 at 3:15 PM

$ATHE Black Friday Sale all around including ATHE. Eat my hairy ass shorts…

0 · Reply

stckmuncher Nov. 28 at 3:13 PM

$ATHE Keep selling at a discount folks, will gladly keep accumulating!

0 · Reply

GA09 Nov. 28 at 1:44 PM

$ATHE The next catalyst to trigger a significant rally will be a partnership or an outright buyout and the EO2 meeting with the FDA planning for Phase 3 trials. CEO has stated (multiple times) that pharma companies have already approached ATHE and are interested in the MOA of 434. Parkinson's Disease is devastating and 434 shows it is working with MSA patients. We will wake up one morning to find the stock up significantly. It is only a matter of time they find a partner or get acquired. CEO wants to bring 434 to patients ASAP and has the experience of getting FDA approvals and also working at biotech companies that were eventually acquired.

1 · Reply

stckmuncher Nov. 28 at 1:11 AM

$ATHE Happy Thanksgiving!

0 · Reply

Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference

Oct 31, 2025, 7:25 AM EDT - 4 weeks ago

Alterity Therapeutics: Appendix 4C – Q1 FY26 Quarterly Cash Flow Report

Oct 9, 2025, 7:25 AM EDT - 2 months ago

Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson's Disease and Movement Disorders

Oct 2, 2025, 7:35 AM EDT - 2 months ago

Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson's Disease and Movement Disorders

Sep 8, 2025, 7:35 AM EDT - 3 months ago

Alterity Therapeutics Raises A$20.0 million in Strategic Placement

Sep 2, 2025, 7:25 AM EDT - 3 months ago

Alterity Therapeutics to Present at the Biotech Showcase

Jul 30, 2025, 7:25 AM EDT - 4 months ago

Appendix 4C – Q4 FY25 Quarterly Cash Flow Report

Jul 28, 2025, 7:25 AM EDT - 4 months ago

Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy

Jul 24, 2025, 7:25 AM EDT - 4 months ago

Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study

Jun 23, 2025, 7:25 AM EDT - 5 months ago

Alterity Therapeutics to Provide Corporate Update in Fireside Chat

May 12, 2025, 7:35 AM EDT - 7 months ago

Alterity Therapeutics Prominently Featured at the International MSA Congress

May 7, 2025, 8:16 AM EDT - 7 months ago

Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress

May 5, 2025, 7:35 AM EDT - 7 months ago

Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy

Apr 30, 2025, 7:35 AM EDT - 7 months ago

Appendix 4C – Q3 FY25 Quarterly Cash Flow Report

Apr 28, 2025, 7:35 AM EDT - 7 months ago

Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium

Apr 10, 2025, 7:35 AM EDT - 8 months ago

Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting

Mar 27, 2025, 7:25 AM EDT - 9 months ago

Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy

Feb 10, 2025, 7:25 AM EST - 10 months ago

Alterity Therapeutics Raises A$40.0 million in Placement

Jan 30, 2025, 7:35 AM EST - 11 months ago

Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy

Jan 24, 2025, 7:35 AM EST - 11 months ago

Appendix 4C – Q2 FY25 Quarterly Cash Flow Report

Jan 9, 2025, 7:25 AM EST - 11 months ago

Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones

Dec 4, 2024, 7:35 AM EST - 1 year ago

Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy

Nov 19, 2024, 7:25 AM EST - 1 year ago

Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary

Nov 12, 2024, 7:35 AM EST - 1 year ago

Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium

Nov 6, 2024, 7:35 AM EST - 1 year ago

Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434

Oct 31, 2024, 7:35 AM EDT - 1 year ago

Appendix 4C – Q1 FY25 Quarterly Cash Flow Report

Oct 14, 2024, 7:35 AM EDT - 1 year ago

Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024

Oct 11, 2024, 7:35 AM EDT - 1 year ago

Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting

Oct 2, 2024, 7:35 AM EDT - 1 year ago

Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson's Disease and Movement Disorders®

Sep 30, 2024, 7:35 AM EDT - 1 year ago

Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer

Sep 23, 2024, 7:35 AM EDT - 1 year ago

Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson's Disease and Movement Disorders®

Jul 31, 2024, 7:35 AM EDT - 1 year ago

Appendix 4C – Q4 FY24 Quarterly Cash Flow Report

Jul 24, 2024, 7:35 AM EDT - 1 year ago

Alterity Therapeutics to Present at MST Financial Webinar

Jul 17, 2024, 7:35 AM EDT - 1 year ago

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

Jul 17, 2024, 7:25 AM EDT - 1 year ago

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

Jun 12, 2024, 7:22 PM EDT - 1 year ago

Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences' Webinar

May 29, 2024, 7:21 PM EDT - 1 year ago

Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study

May 8, 2024, 7:25 AM EDT - 1 year ago

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review

Apr 30, 2024, 7:25 AM EDT - 1 year ago

Appendix 4C – Q3 FY24 Quarterly Cash Flow Report

Apr 29, 2024, 7:25 AM EDT - 1 year ago

Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich's Ataxia

Apr 17, 2024, 7:25 AM EDT - 1 year ago

Alterity Therapeutics Parkinson's Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting

Apr 10, 2024, 7:25 AM EDT - 1 year ago

Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024

Mar 26, 2024, 10:25 AM EDT - 1 year ago

Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund

Feb 20, 2024, 10:25 AM EST - 1 year ago

Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting

Feb 6, 2024, 7:25 AM EST - 1 year ago

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review

Jan 29, 2024, 7:24 AM EST - 2 years ago

Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week

Dec 21, 2023, 12:30 AM EST - 2 years ago

Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer

Dec 4, 2023, 4:35 PM EST - 2 years ago

Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical Progress

Dec 4, 2023, 7:25 AM EST - 2 years ago

Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson's Disease

Nov 27, 2023, 7:25 AM EST - 2 years ago

Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy

stckmuncher Dec. 2 at 12:35 AM

$ATHE Can anyone explain what in in the furry fuck is going on?

0 · Reply

Dingo2 Dec. 1 at 4:34 PM

$ATHE LOL - thinly traded and someone is parking 47k on ask? Sure…

1 · Reply

stckmuncher Dec. 1 at 3:48 AM

$ATHE HUGE YEAR COMING!!!!!!!!!!!!!!!!

0 · Reply

GA09 Nov. 30 at 11:40 PM

$ATHE https://www.youtube.com/watch?v=yZo-2w7r3cg Presentation at the Bell Potter Conference 2025

2 · Reply

GA09 Nov. 30 at 11:39 PM

$ATHE The CEO's presentation at the Bell Potter Healthcare Conference 2025 is now available in the Events Section on their website.

0 · Reply

stckmuncher Nov. 28 at 3:16 PM

$ATHE

0 · Reply

stckmuncher Nov. 28 at 3:15 PM

$ATHE Black Friday Sale all around including ATHE. Eat my hairy ass shorts…

0 · Reply

stckmuncher Nov. 28 at 3:13 PM

$ATHE Keep selling at a discount folks, will gladly keep accumulating!

0 · Reply

GA09 Nov. 28 at 1:44 PM

1 · Reply

stckmuncher Nov. 28 at 1:11 AM

$ATHE Happy Thanksgiving!

0 · Reply

stckmuncher Nov. 28 at 12:53 AM

$ATHE I got 99 problems but ATHE ain’t one of dem…

0 · Reply

stckmuncher Nov. 27 at 10:34 PM

$ATHE Predicitng $25+ prior to 3Q 2026.

0 · Reply

Double__Down Nov. 27 at 7:10 PM

$ATHE Happy Thanksgiving! Our financial situations could be drastically different this time next year! Big things coming

2 · Reply

stckmuncher Nov. 27 at 3:56 AM

$ATHE had me half chub today. Thoughts of The Thanksgiving meal tomorrow brought me to three quarters chub. Lions game and thought of victory brought me to full chub. LFG!!!!

1 · Reply

DaBullRunner Nov. 25 at 3:52 PM

$OSRH next time stop ignoring my calls 🚨IMM🚨is going to be the next $ATHE 👇💰💰💰 $EPWK $RYET $IVP let’s get it

0 · Reply

GA09 Nov. 24 at 11:22 PM

$ATHE This one will open significantly higher (sooner rather than later) after they get a strategic partner.

0 · Reply

stckmuncher Nov. 24 at 1:20 AM

$ATHE My buddy has 250 shares of this! Working on my first 100…

1 · Reply

stckmuncher Nov. 23 at 1:01 PM

$ATHE LETS GO!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

0 · Reply

tommy_john Nov. 22 at 6:56 AM

$ATHE the gap at 3.44 closed nov 7th. Chart is set up for a reclaim of uptrend in December. Over the years this has really popped in Q1. They diluted already so as we wait for news or partner or buyout they are on pace for a blowout in 2026. We could see a morning spike in the coming weeks. Worth a trade soon.

1 · Reply

theflynews Nov. 20 at 7:15 PM

Meet Alterity Therapeutics: Fly exclusive interview with CEO David Stamler - $ATHE - https://thefly.com/permalinks/entry.php/ATHEid4243910?

0 · Reply

GA09 Nov. 20 at 2:05 PM

$ATHE I missed the presentation last night. I am waiting for them to post it in their Events section on their site.

0 · Reply

stckmuncher Nov. 19 at 2:46 AM

$ATHE Beautiful presentation thus far!

1 · Reply

Market Cap	29.62M
Revenue (ttm)	0.00
Net Income (ttm)	-7.87M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	5,500
Avg Vol	109,424
Day's Range	N/A - N/A
Shares Out	8.87M
Stochastic %K	44%
Beta	0.02
Analysts	Strong Sell
Price Target	$11.00